Start: April 11, 2019
End: May 31, 2021
Enrollment: 26
AGB101 is an extended-release, low-dose preparation of levetiracetam, a drug approved by the U.S. Food and Drug Administration to treat certain types of seizures. It works by decreasing abnormal excitement in the brain. In this study researchers are investigating whether the drug can reduce abnormal brain activity and improve memory. Participants will be randomly assigned to take a capsule of the study drug or a placebo once daily for two weeks. After a four-week washout period (i.e., not taking the study drug or placebo), participants will rotate groups and take either the study drug or a placebo for another two weeks.
Minimum Age: 55 Years
Maximum Age: 75 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: Medical College of Wisconsin
Collaborator Sponsor
Source: ClinicalTrials.gov ID: NCT03461861